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ERK1/2 inactivation
Yong Tang1†, Fenghua Liu1†, Chunning Zheng2, Shaochuan Sun2* and Yingsheng Jiang2Abstract
Objectives: To study the hypothesis that gemcitabine treatment augments the chemoresistance to gemcitabine by
clusterin (sCLU) upregulation. Clusterin inhibition could augment the chemosensitivity of human pancreatic cancer
cells by inhibition of clusterin-dependent pERK1/2 activation.
Methods: Clusterin was silenced by serial concentration of OGX-011 transfection in pancreatic cancer MIAPaCa-2
and BxPC-3 cell lines, then treated with serial concentration of gemcitabine. After the cells were treated with
OGX-011 for 8 h, the cells were then treated with 5 μM ERK inhibitor PD98059 for 18 h or transfected with a
wt-pERK-expressing plasmid into these cells for 24 h, after which the cells were treated with 1.0 uM gemcitabine for
24–72 h. Cell proliferation was determined by MTT. Apoptosis was quantified by flow cytometry,.sCLU and pERK1/2
production was analyzed by western blot, and sCLU mRNA was analyzed by RT-PCR. Xenograft of established
tumors was used to evaluate primary tumor growth and apoptosis after treatment with gemcitabine alone or in
combination with OGX-011. Phosphorylated ERK1/2 and sCLU levels in tumor tissues were measured by TUNEL
analysis.
Results: As detected by MTT and FACS assay, a combination of gemcitabine +OGX-011 reflected the
chemotherapeutic sensitivity and increased the gemcitabine -induced apoptosis in MIAPaCa-2 and BxPC-3 cells.
Western blotting and RT-PCR analysis revealed that the expression of clusterin was higher in gemcitabine -resistant
MIAPaCa-2 cells, however, decreased significantly after pretreatment with OGX-011. Furthermore, the OGX-011 or
combination of gemcitabine +OGX-011 decreased the gemcitabine -induced activation of pERK1/2.
wt-pERK-re-expression decreased OGX-011+ gemcitabine -induced apoptosis. Finally, OGX-011 in combination with
gemcitabine substantially decreased the in vivo tumor growth and promoted apoptosis. Taken together, clusterin
confers gmcitabine resistance in pancreatic cancer cells.
Conclusions: Knockdown of clusterin by OGX-011 transfection sensitizes pancreatic cancer cells to gemcitabine by
inhibition of gemcitabine -induced clusterin-pERK1/2 activation.
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Pancreatic cancer has the worst prognosis of all major
cancers, with an overall 5-year survival rate of around
5% [1]. The current clinical standard of care for
advanced pancreatic cancer is gemcitabine, a cytotoxic
nucleoside analogue. Gemcitabine results in a tumor re-
sponse rate of 12% and offers a median survival time of
5 months [2]. Unfortunately, this means that the best
current treatment offers very modest benefits. Recent
studies have indicated that targeted therapies in combin-
ation with gemcitabine can have statistically significant
benefits [3]. However, the results to date remain meager,
and new approaches to improving the effectiveness of
gemcitabine are needed. One of the targets considered
for combination therapy that has generated wide atten-
tion is clusterin [4].
Clusterin, also known as testosterone-repressed pros-
tate message-2 (TRPM-2), sulfated glycoprotein-2 (SGP-
2), apolipoprotein J (Apo J) or SP40, is a ubiquitous
heterodimeric-secreted glycoprotein of 75–80 kDa. A
single-copy gene in humans of nine exons, spanning
over 16 kb and located on chromosome 8p21-p12,
encodes an mRNA of approximately 2 kb, which directs
the synthesis of a 449-amino acid primary polypeptides
chain [5]. Recent focus has turned to clusterin as a key
contributor to chemoresistance to anticancer agents. Its
role has been documented in prostate cancer for pacli-
taxel/docetaxel resistance [6] as well as in renal [7],
breast [8], and lung tumor cells [9]. Moreover, it is ab-
normally upregulated in numerous advanced stage and
metastatic cancers spanning gastric cancer [10], bladder
[11], cervical [12], breast [13],ovarian [14], hepatocellular
[15], colorectal [16], renal [17], prostate [18], head and
neck [19], lung carcinomas [20], melanoma [21]and
lymphoma [22].It is noteworthy that only the cytoplas-
mic/secretory clusterin form (sCLU), and not the nu-
clear form, is expressed in aggressive late stage tumors,
which is in line with its antiapoptotic function [23].
Many reports also document that sCLUc inhibits
mitochondrial apoptosis. For example, sCLUc suppresses
p53-activating stress signals and stabilizes cytosolic
Ku70-Bax protein complex to inhibit Bax activation [24].
sCLUc specifically interacts with conformationally
altered Bax to inhibit apoptosis in response to che-
motherapeutic drugs [25]. sCLU sliencing alters the ratio
of anti-apoptotic Bcl-2 family members, disrupting
Ku70/Bax complexes and Bax activation [24,25]. In
addition, sCLU increases Akt phosphorylation levels and
cell survival rates [26]. sCLU induces epithelial-
mesenchymal transformation by increasing Smad2/3
stability and enhancing TGF-β-mediated Smad tran-
scriptional activity [27]. sCLU also promotes prostate
cancer cell survival by increasing NF-κB nuclear transac-
tivation, acting as a ubiquitin-binding protein thatenhances COMMD1 and I-kB proteasomal degradation
via interaction with E3 ligase family members [28]. sCLU
sliencing stabilized COMMD1 and I-κB, suppressing NF-
κB translocation to the nucleus, and suppressing NF-κB-
regulated gene signatures. Thus, sCLU has a key role in
preventing apoptosis induced by cytotoxic agents and
has the potential to be targeted for cancer therapy.
It has recently reported sCLU was overexpressed in
pancreatic cancer tissues and sCLU overexpression con-
fered gmcitabine resistance in pancreatic cancer cells,.
Furthermore,sCLU silencing sensitized pancreatic cancer
cells to gemcitabine chemotherapy, however the mech-
anism is still unclear [29].
ERK1/2 is an important subfamily of mitogen-
activated protein kinases that control a broad range of
cellular activities and physiological processes. ERK1/2
can be activated transiently or persistently by MEK1/2
and upstream MAP3Ks in conjunction with regulation
and involvement of scaffolding proteins and phospha-
tases [30]. There is abundant evidence that survival fac-
tors can use the ERK1/2 pathway to increase the
expression of several pro-survival BCL-2 proteins, not-
ably BCL-2, BCL-xL and MCL-1, by promoting de novo
gene expression in a variety of cell types [31]. Clearly the
ERK1/2 pathway can regulate several members of the
BCL-2 protein family to achieve cell survival. ERK1/2
signalling can provide protection against chemothera-
peutic cytotoxic drugs.
It has shown previously sCLU plays an important role
in astrogliosis by stimulating the proliferation of astro-
cytes through activation of the extracellular signal-
regulated kinase 1/2 signaling pathway [32]. Shim and
Chou et al. also found significant relation between sCLU
and ERK1/2 expression [33,34]. We therefore suggested
that sCLU silencing sensitized pancreatic cancer cells to
gemcitabine chemotherapy may via ERK1/2 signaling
pathway.
sCLU is not a traditional druggable target and can
only be targeted at mRNA levels. An antisense inhibi-
tor targeting the translation initiation site of human
exon II CLU (OGX-011) was developed at the Univer-
sity of British Columbia and out-licensed to Onco-
GeneX Pharmaceuticals Inc. OGX-011, or custirsen, is
a second-generation antisense oligonucleotide with a
long tissue half-life of 7 days, which potently sup-
presses sCLU levels in vitro and in vivo. OGX-011
improved the efficacy of chemotherapy, radiation, and
hormone withdrawal by inhibiting expression of sCLU
and enhancing apoptotic rates in preclinical xenograft
models of prostate, lung, renal cell, breast, and other
cancers [35-39].
In this study, we study the effect of sCLU silencing by
OGX-011 on sensitizion of pancreatic cancer cells to
gemcitabine chemotherapy, and eluated the mechanisms.
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Cell culture
The human pancreatic cancer MIAPaCa-2 cells resistant
to gemcitabine and BxPC-3 cells sensitive to gemcitabine
[38] were purchased from American Type Culture Col-
lection. They were routinely cultured in DMEM supple-
mented with 10% fetal bovine serum in a 37°C incubator
in a humidified atmosphere of 5% CO2.Reagents and antibodies
OGX-011 was purchased from OncoGenex Technologies.
The antisense oligonucleotides were second-generation 21-
mer antisense oligonucleotides with a 20-O-(2-methoxy)
ethyl modification. The antisense oligonucleotide clusterin
sequence corresponding to the human clusterin initiation
site was 50-CAGCAGCAGAGTCTTCATCAT-30 and
designated OGX-011 (OncoGenex Technologies). The
MEK inhibitor PD98059 was products of Calbiochem (San
Diego, CA, USA), Antibodies for sCLU, and phospho-
specific or the total form of antibodies against ERK1/2,
GAPDH were purchased from Santa Cruz Biotechnology,
Santa Cruz, CA, USA).Construction of transient transfection with a plasmid
expressing human wt-pERK
Total RNA was extracted from PANC-1 cells using TRI-
zol reagent (Invitrogen, CA, United States), according to
the manufacturer’s protocol. The cDNAs were synthe-
sized using the TaKaRa RNA polymerase chain reaction
(PCR) Kit (TaKaRa, Japan). A full-length cDNA encod-
ing human wt-pERK was cloned by PCR using 500 ng
cDNA as a template and primers containing HindIII and
BamHI restriction enzyme sites. The PCR products were
ligated into pcDNA3.1 (Invitrogen, CA, United States)
to create the plasmid pcDNA3.1- wt-pERK. MIA PaCa-2
and BxPC-3 cells were transfected with the pcDNA3.1
vector or pcDNA3.1- wt-pERK using FuGENE (Roche
Diagnostic GmbH, Mannheim, Germany), according to
the manufacturer’s protocol.Transient transfection
MIA PaCa-2 and BxPC-3 cells were treated with OGX-
011(400,800,1000,1200 nM) for 24 h, then the cells were
cultured overnight in 6-well plates and transfected with
pcDNA3.1- wt-pERK using Lipofectamine Plus (Invitro-
gen) in 1 ml serum-free medium according to the manu-
facturer’s instructions. Four hours post-transfection,
each well was supplemented with 1 ml of medium con-
taining 20% FBS. Twenty-four hours post-transfection,
media were removed and the cells were harvested or
treated with gemcitabine for a further 24 hours.Western blotting assay
About 25 μg protein was extracted, separated by 10% so-
dium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE), transferred onto polyvinylidene fluoride
membranes, and then reacted with primary rabbit
antibodies against sCLU(1:100), pERK1/2(1:100) and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
(1:200). After being extensively washed with PBS con-
taining 0.1% Triton X-100, the membranes were
incubated with alkaline phosphatase-conjugated goat
anti-rabbit antibody for 30 minutes at room temperature.
The bands were visualized using 1-step™ NBT/BCIP
reagents (Thermo Fisher Scientific, Rockford, IL, USA)
and detected by the Alpha Imager (Alpha Innotech, San
Leandro, CA, USA).
RT-PCR assay
The mRNA extraction and RT reaction for synthesizing
the first-strand cDNA was carried out according to the




CAGGAGACAACC-50for GAPDH. The PCR conditions
consisted of an initial denaturation at 95°C for 3 min,
followed by 28 cycles of amplification (95°C for 15 s,
58°C for 15 s, and 72°C for 20 s) and a final extension
step of 5 min at 72°C. PCR products were analyzed on a
1.2% agarose gel. The significance of differences was
evaluated with Student’s t-test. The mean ± SD are
shown in the figures. P < 0.05 was considered to be sta-
tistically significant.
FACS analysis
To identify the induction of apoptosis, cells underwent
propidium iodide (PI) staining and fluorescence-
activated cell sorting (FACS) as to the manufacture’s in-
struction. In brief, cells were plated at a density of
1 × 105 cells/ml. After allowing 24 hours for cell adher-
ence, cells were transfected and/or treated. Cells were
collected by gentle trypsinization, washed in phosphate-
buffered saline (PBS), pelleted by centrifugation and
fixed in 70% ethanol. Immediately prior to staining, cells
were washed twice in PBS and resuspended in PBS con-
taining RNAse A (20 μg/ml). Cells were stained with
propidium iodide (final concentration 10 μg/ml) for
10 min at room temperature. Samples were analyzed by
FACS (FL-3 channel) using a Beckman Coulter Counter
Epics XL flow cytometer (Beckman Coulter, Miami, FL,
USA). For each sample, 50,000 events were collected
and stored for subsequent analysis using EXPO software
(version 2.0; Applied Cytometry Systems, Sheffield, UK).
The percentage of cells in the sub-G0 phase was quanti-
tated as an estimate of cells undergoing apoptosis.
Figure 1 Induction of sCLU in a time and dose dependent
fashion by gemcitabine treatment. A. Western analysis showing
sCLU expression after 2–24 hours treatment with 0.5 nM
gemcitabine. Induction of sCLU is evident in chemo-sensitive BxPC-3
cells when treated with high doses of gemcitabine but not in
MIAPaCa-2, in which the high levels of sCLU remained unchanged.
B. Western analysis showing sCLU expression in cell extracts after
12 hours treatment with 0.1-1.0 nM gemcitabine. sCLU increased in
gemcitabine -sensitive BxPC-3 cells at different doses. At difference,
expression of sCLU was unchanged in the MIAPaCa-2-resistant cells.
The data shown are representative of three independent
experiments.
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Cells were plated at 2 × 103 cells per well in 96-well
plates for six days. Cytotoxicity was determined by 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium brom-
ide assay (MTT, Trevigen, Inc., Gaithersburg, MD) in
accordance with the manufacturer’s instructions. Plates
were read using a Vmax microplate spectrophotometer
(Molecular Devices, Sunnyvale, CA) at a wavelength of
570 nm corrected to 650 nm and normalized to controls.
Each independent experiment was done thrice, with 10
determinations for each condition tested. At identical
time points,cells were trypsinized to form a single cell
suspension. Intact cells, determined by trypan blue ex-
clusion, were counted using a Neubauer hemocytometer
(Hausser Scientific, Horsham, PA). Cell counts were
used to confirm MTT results.
Antitumor study
MIAPaCa-2 or BxPC-3 cells (107) were injected into the
pancreas of SCID mice. Four weeks after tumor implant-
ation, the mice were assigned to one of the following
four treatment groups (n = 10 each): (a) vehicle control;
(b) gemcitabine, biweekly treatment 80 mg/kg/injection;
(c) OGX-011, biweekly treatment 0.35mg/kg/injection;
(d) gemcitabine plus OGX-011, with gemcitabine on
Monday and Thursday and OGX-011 on Wednesday
and Saturday. All groups received treatment via i.p. in-
jection. Mice in all groups were killed after 5 weeks of
treatment. Orthotopic tumors were harvested and
weighed.
In vivo apoptosis assay
Five serial sections (5 um thick) were obtained for each
frozen tumor, mounted on glass slides, and then fixed in
4% paraformaldehyde. The first section was processed
for H&E staining. Apoptosis was evaluated by terminal
transferase dUTP nick end labeling [TUNEL] staining
using the Apoptag Peroxidase In Situ Detection Kit
S7100 [Chemicon] according to the manufacturer’s
instructions.
Statistical analysis
All statistical analyses were performed using the
SPSS13.0 software. The results were presented as
means ± SD of two-three replicate assays. Differences be-
tween different groups were assessed using X2 or t-test.
A P value of <0.05 was considered to indicate statistical
significance.
Results
Gemcitabine treatment upregulates sCLU
To investigate whether upregulation of sCLU expression
is a cause or a result of gemcitabine -induced resistance,
both MIAPaCa-2(resistant to gemcitabine) and BxPC-3(sensitive to gemcitabine) cells [40] cells were treated
with gemcitabine at 0.5uM for 2–24 h (Figure 1A) or at
concentrations 0.1-1.0 uM for 12 h (Figure 1B). Sensitive
BxPC-3 cells rapidly responded (sCLU up-regulation
peaked by 12 h and began decreasing by 16 h by increas-
ing sCLU expression level under 1.0 uM doses of gemci-
tabine. MIAPaCa-2 cells already expressing higher sCLU
levels, did not further express sCLU following gemcita-
bine treatment. Considering that changes in sCLU ex-
pression seem to be independent of sCLU mRNA, which
did not change significantly as indicated by real-time
PCR (data not shown). These results suggested that
post-translational modification of sCLU may be altered
in response to gemcitabine treatment.
Knockdown of sCLU sensitizes pancreatic cancer cells to
gemcitabine chemotherapy
Resistance to anticancer agents is one of the primary
impediments to effective cancer therapy. Both intrinsic
and acquired mechanisms have been implicated in drug
resistance but it remains controversial which mechan-
isms are responsible that lead to failure of therapy in
cancer patients.
In the present study, MIAPaCa-2 and BxPC-3 cell
lines were treated with 1.0 uM of gemcitabine for
24 hours, significant apoptosis (21%) was shown in
BxPC-3 cell lines,compared with control(P < 0.05). How-
ever, in MIAPaCa-2 cells, 1. 0uM of gemcitabine treat-
ment did not induce significant apoptosis (P > 0.05). It
has shown above only low levels of apoptosis were
detected in pancreatic cancer cells following 1.0 uM of
Figure 3 ERK inhibitor PD98059 inactivate ERK1/2 in untreated
and gemcitabine-treated breast cancer cells. A, BxPC-3 and
MIAPaCa-2 cells were exposed to the indicated concentrations of
gemcitabine for 18 hr. The cells were then lysed and subjected to
WB analysis to monitor pERK1/2 (Thr42/Tyr44) expression as
described in Materials and Methods. B, BxPC-3 and MIAPaCa-2 cells
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sic and simultaneous induction of clusterin by gemcita-
bine. Indeed, knockdown of sCLU by 1200 nM OGX-
011(maximally reduced sCLU expression) led to a sig-
nificant increase in gemcitabine-induced apoptosis in
both MIAPaCa-2 cells and BxPC-3 cells by FACS ana-
lysis (Figure 2A,*P < 0.05). However, knockdown of sCLU
itself did not affact apoptosis of MIAPaCa-2 cells and
BxPC-3 cells (Figure 2A).
On the other hand, cellular viability was studied under
experimental conditions similar to this described above.
Figure 2B shows significantly less viability of MIAPaCa-2
cells and BxPC-3 cells pre-treated with 1200nM OGX-
011(*P < 0.05). Together, the aforementioned data
indicate that silencing sCLU by OGX-011 enhanced
gemcitabine toxicity in the pancreatic cancer cells. Con-
trol oligodeoxynucleotide did not have obvious effect on
apoptosis or growth in both cells (data not shown).were exposed (18 hours) to either 5 μM PD98059, 0.5-1.0 μM of
gemcitabine, or the combination, after which proteins were
prepared and subjected to WB as described above to monitor
pERK1/2 expression. For (A) and (B), lanes were loaded with 25 μg of
protein; blots were then stripped and re-probed with GAPDH to
ensure equivalent loading and transfer. Representative results are
shown; two additional studies yielded equivalent results.ERK inhibitor PD98059 inactivates ERK1/2 in untreated
and gemcitabine-treated pancreatic cancer cells
Studies were then performed to assess the effects of
gemcitabine on ERK1/2 activation in BxPC-3 and
MIAPaCa-2 cells. Exposure to 0.5-1.0 μM gemcitabine
(18 hr) induced ERK1/2 activation in BxPC-3 cells
(Figure 3A).In MIAPaCa-2 cells, 0.5-1.0 μM gemcitabine
treatment did not affact ERK1/2 activation (Figure 3A).
However, co-administration of the 5 μM ERK inhibitor
PD98059 essentially abrogated expression of pERK1/2 in
both untreated and gemcitabine -treated BxPC-3
(Figure 3B) and MIAPaCa-2 cells (Figure 3B). These
findings indicate that in breast cancer cells, 5 μM ERK
inhibitor PD98059 essentially abrogate basal ERK1/2 ac-
tivation as well as gemcitabine -mediated ERK1/2
activation.Figure 2 Targeting sCLU by OGX-011 sensitizes pancreatic cancer cel
transfected either with OGX-011 (1200nM) and then challenged with gemc
011 enhanced gemcitabine toxicity in both of the cells. B, Comparative via
sliencing. Cells were cultured in 96-well plates, then transfected either with
with gemcitabine. Seventy-two hours after drug addition ,cell viability was
experiments (*P< 0.05).Inactivate ERK1/2 by ERK inhibitor PD98059 sensitizes
pancreatic cancer cells to gemcitabine treatment
To determine whether ERK1/2 protects pancreatic can-
cer cells from gemcitabine -induced cell death or not,
5 μM PD98059 was used to inhibit pERK1/2. BxPC-3
and MIAPaCa-2 cells was treated with 1.0 μM of gemci-
tabine. The results shown both BxPC-3 and MIAPaCa-2
cells were significantly more sensitive to gemcitabine
-mediated apoptosis compared to cells exposed to gem-
citabine in the absence of PD98059 (P < 0.05; Figure 4).ls to gemcitabine treatment. A, BxPC-3 and MIAPaCa-2 cells were
itabine dose of 1.0 uM at 24 h. FACS analysis demonstrating that OGX-
bility of MIAPaCa-2 cells and BxPC-3 cells before and after sCLU
OGX-011. Twenty-four hours after last transfection, cells were treated
estimated. The data shown are representative of three independent
Figure 5 Knockdown of clusterin sensitizes pancreatic cancer
cells to gemcitabine via pERK1/2 inactivation. A, MIAPaCa-2 cells
were treated with 1200 nM OGX-011 for 24 hours, after which
proteins were prepared and subjected to Western blot as described
above to monitor pERK1/2 expression. B, BxPC-3 and MIAPaCa-2
cells were treated with 1200 nM OGX-011 for 8 hours, then a wt-
pERK-expressing plasmid was transfected into these cells for
24 hours, after which the cells were treated with 1.0 uM
gemcitabine for 24 hours. Gemcitabine -induced cell death was
determined by FACS. Representative results are shown; two
additional studies yielded equivalent results (*P< 0.05).
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cells and BxPC-3 cells pre-treated with 5 μM PD98059 ,
then treated with 1.0 nM gemcitabine(data not shown).
These findings argue that ERK1/2 inactivation plays a
significant functional role in the potentiation of gemcita-
bine lethality.
Knockdown of sCLU sensitizes pancreatic cancer cells to
gemcitabine treatment via pERK1/2 inactivation
We first evaluated the effect of sCLU silencing on the
pERK1/2 activation in MIAPaCa-2 cells. MIAPaCa-2
cells were treated with 1200 nM OGX-011 for 24 hours.
Figure 5A shows significant decrease in pERK1/2 activa-
tion in the two cells. BxPC-3 has no basic pERK1/2 ex-
pression, so it only used for pERK re-expression. It has
shown sCLU silencing itself did not affact apoptosis and
growth of MIAPaCa-2 cells and BxPC-3 cells. However,
sCLU silencing combined with 1200 nM OGX-011 treat-
ment led to a significant increase in gemcitabine-
induced apoptosis in both MIAPaCa-2 cells and BxPC-3
cells by FACS analysi (Figure 2A).We next explored
whether pERK re-expression could eliminate the effects
of sCLU silencing on gemcitabine-induced apoptosis.
BxPC-3 and MIAPaCa-2 cells were treated with 1200
nM OGX-011 for 8 hours, then a wt-pERK-expressing
plasmid was transfected into these cells, after transfec-
tion for 24 hours ,the cells were treated with 1.0 uM
gemcitabine for another 24 hours. While vector transfec-
tion did not decrease gemcitabine-induced apoptosis inFigure 4 Inhibition of ERK1/2 sensitizes BxPC-3 and MIAPaCa-2
cells to gemcitabine -induced apoptosis. BxPC-3 and MIAPaCa-2
cells were treated with 5 μM PD98059 for 18 hours ,then the cells
were exposed to 1.0 μM gemcitabine for 24 hours. Gemcitabine
-induced cell death was determined by FACS. All values represent
the means ± SD for duplicate determinations performed on three
separate occasions. * Significantly greater than values obtained for
cells cultured in the absence of PD98059; P <0.05).both MIAPaCa-2 and BxPC-3 cells (data not shown). How-
ever wt-pERK-re-expressing in BxPC-3 and MIAPaCa-2
cells significantly decrease in gemcitabine-induced apop-
tosis (Figure 5B). These data demonstrated knockdown of
clusterin sensitizes pancreatic cancer cells to gemcitabine
via pERK1/2 dependent pathway.
In vivo inhibition of tumor growth
Four, two, and three deaths were noted in the vehicle
control, gemcitabine-, and OGX-011-treated groups, re-
spectively, before the end of the 5-week treatment
period because of large tumors. Conversely, all mice re-
ceiving gemcitabine and OGX-011 in combination were
alive and exhibited a healthier appearance. Orthotopic
tumors were dissected free of surrounding normal tis-
sues and weighed. As shown in Figure 6A, gemcitabine
alone did not significantly reduced tumor weights in
BxPC-3 and MIAPaCa-2 cells compared to the controls,
however, gemcitabine in combination with OGX-011 sig-
nificantly reduced tumor weights by 5-fold (P < 0.001) in
MIAPaCa-2 cell relative to the vehicle control, and 3-
fold (P < 0.001) in BxPC-3 cell relative to the vehicle
control. The further decrease in tumor weights observed
Figure 6 In vivo inhibition of tumor growth of gemcitabine in combination with OGX-011. A, Tumor weights in grams (g) in mice treated
with the vehicle control, gemcitabine (gem.; 80 mg/kg biweekly, i.p.), OGX-011 (0.25 mg/kg biweekly, i.p.) alone or in combination. Significantly
different from the vehicle control group or the gemcitabine-treated group (P <0.01). B, TUNEL-positive cells in the vehicle control, gemcitabine or
OGX-011 alone or in combination. Significantly different from the vehicle control group (*P < 0.01). C, Effects of OGX-011 on tumor tissues in vivo.
Representative Western blots showing the levels of pERK1/2 in the vehicle control, gemcitabine or OGX-011 alone or in combination. Similar
results were obtained from four separate animals in each group. Significantly different from the combined group or the gemcitabine-treated
group (*P <0.01).
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different from the gemcitabine monotherapy group
(P < 0.001). OGX-011 alone failed to inhibit tumor
growth.
To investigate if the mechanisms involved in the induc-
tion of apoptosis in targeted lesions of tumor xenografts
represented a phenotypic response of BxPC-3 and
MIAPaCa-2 tumors, the TUNEL assay was performed.
Representative results are shown in Figure 6B. In the
combination treatment groups of BxPC-3 and MIAPaCa-2 tumors, TUNEL-positive cells in tumor sections pre-
sented with fragmented nuclei. As shown in Figure 6B,
gemcitabine (80 mg/kg) or OGX-011 alone did not pro-
duce significant increases in apoptosis compared with
the vehicle control. However, the extent of apoptosis was
significantly increased by 5-fold (P < 0.002) in MIAPaCa-
2 tumors ,and 3-fold (P < 0.001) in BxPC-3 tumors, trea-
ted with gemcitabine and OGX-011 in combination.
To determine whether inhibition of Clusterin by
OGX-011 enhances sensitivity to gemcitabine via
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sion by western-blotting assay. As shown in Figure 6C,
gemcitabine treatment did not activate pERK1/2 in the
MIAPaCa-2 tumors, and gemcitabine treatment signi-
cantly activated pERK1/2 in the BxPC-3 tumors. How-
ever, gemcitabine in combination with OGX-011
significantly inhibited pERK1/2 activation.We therefore
think that sCLU sliencing sensitizes pancreatic cancer
cells to gemcitabine chemotherapy by inhibiton of
ERK1/2 activation.Discussion
Pancreatic cancer is one of the most difficult human
cancers to treat due to the inability to detect disease at
an early stage and the lack of effective therapies. Al-
though there has been some progress in the use of
improved diagnostic methods and development of novel
targeted therapies, the overall survival rate has not
improved over the last decade [39]. The most commonly
used chemotherapy for pancreatic cancer, gemcitabine,
has modest clinical benefit and may not improve overall
survival to a clinically meaningful degree [40,41]. The
lack of significant clinical response of pancreatic cancer
patients to chemotherapy is likely due to the inherent
chemoresistance of pancreatic cancer cells as well as
impaired drug delivery pathways [42]. Understanding the
underlying mechanisms of drug resistance in pancreatic
cancer is critical to develop new effective treatments for
this deadly disease.
sCLU expression has been implicated in chemoresis-
tance in several other cancer types [43-45], including
pancreatic cancer [29]. Because the resistance of tumor
cells to various available chemotherapeutic agents has
been one of the major factors leading to poor survival in
pancreatic cancer patients, we therefore hypothesized
that sCLU confers chemoresistance to pancreatic cancer
cells.
In this study, we demonstrated that sCLU was corre-
lated with inherent resistance both in vitro and in vivo.
We found that high levels of sCLU in pancreatic cancer
MIAPaCa-2 cell line was correlated with gemcitabine re-
sistance, low levels of sCLU in BxPC-3 cells was sensi-
tive to gemcitabine .To demonstrate the role of sCLU in
gemcitabine resistance, we manipulated the endogenous
level of sCLU in a gemcitabine -sensitive BxPC-3 cell
line and a gemcitabine -resistant MIAPaCa-2 cell line.
We found that gemcitabine -sensitive BxPC-3 cells be-
came more resistant to gemcitabine when endogenous
sCLU expression was up-regulated. Conversely, gemcita-
bine -resistant MIAPaCa-2 cells became more sensitive
to gemcitabine and more apoptotic in vitro and in vivo
when endogenous sCLU expression was down-regulated
by GOX-011 treatment. These results indicated that highlevels of endogenous sCLU were involved in the gemci-
tabine resistance of ovarian cancer cells.
Acquired drug resistance is also thought to be a reason
for the limited benefit of most pancreatic cancer therap-
ies.In the present study, we found treatment by gemcita-
bine increased sCLU expression in BxPC-3 cells,
suggesting that sCLU upregulation is likely to be an
adaptative response that mediates chemoresistance.We
also investigated whether anticlusterin treatment sensi-
tized BxPC-3 cells to gemcitabine.
GOX-011 efficiently inhibited sCLU expression in
BxPC-3 cell lines, and this activity was associated with a
increase in cell apoptosis in gemcitabine-treated BxPC-3
cells in vivo and vitro. This was indicated that increased
sCLU, expression was correlates with gemcitabine resist-
ance in pancreatic adenocarcinoma cells. These results
provide preclinical proof of principle for the use of
OGX-011 as a novel therapeutic strategy for gemcitabine
resistance in the treatment of pancreatic cancer.
Though sCLU confers gmcitabine resistance in pan-
creatic cancer cells, however, the signaling pathway was
unclear. ERK activation has been identified as a potential
survival pathway in several tumor types [46], and recent
studies show that ERKs may also be activated in re-
sponse to chemotherapeutic drugs [47-50], and pERK1/2
played critical roles in drug resistance [51]. Our in vitro
and in vivo studies here indicated that pERK1/2 play sig-
nificant roles in gemcitabine resistance to pancreatic
cancer cells. Most importantly, we demonstrated that
blocking pERK1/2 enhanced the chemotherapeutic po-
tential of gemcitabine in pancreatic cancer cells in vitro.
ERK1/2 inhibitors in combination with chemotherapeu-
tic drugs might be a better option to treat patients with
pancreatic cancer than drugs alone.
It has shown previously sCLU plays an important role
in regulating ERK1/2 signal [32-34].We next study
whether sCLU silencing sensitized pancreatic cancer
cells to gemcitabine chemotherapy may via ERK1/2 sig-
nal. Our results shown sCLU sliencing by OGX-011 sen-
sitizes pancreatic cancer cells to gemcitabine treatment,
followed by inhibition of pERK1/2 activation. Con-
versely, transfection with a constitutively active wt-
pERK1/2 construct promotes gemcitabine resistance.
These data demonstrated sCLU sliencing sensitizes pan-
creatic cancer cells to gemcitabine via pERK1/2
dependent signaling pathway.
In conclusion, gemcitabine may influence pancreatic
cancer behavior via the upregulation of sCLU, which
might play a major role in the effects of gemcitabine,
protecting pancreatic cancer cells from the effects of
gemcitabine. Inherent chemoresistance of pancreatic
cancer cells to gemcitabine may be correlated to sCLU.
Blocking sCLU, on the other hand, reverses the drug’s
unwanted effects on cancer cell apoptosis and survival.
Tang et al. Journal of Experimental & Clinical Cancer Research 2012, 31:73 Page 9 of 10
http://www.jeccr.com/content/31/1/73In addition, our studies have firmly established a role for
sCLU as a cell survival gene that is increased after gem-
citabine chemotherapy to inhibit tumor cell death. The
inhibition of sCLU, using OGX-011, enhances the cyto-
toxic effects of chemotherapy agents via pERK1/2
dependent signaling pathway.
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